Reports Q2 revenue $117.72M, consensus $109.69M. “The strong results of our commercial business in the second quarter reflect the early returns on our substantial investment to help improve the ability of physicians to recognize and treat hypercortisolism. Korlym is an excellent treatment for patients with Cushing’s syndrome and there are many eligible patients who have yet to receive it. We are confident in the growth potential of our Cushing’s syndrome business and are raising our 2023 revenue guidance again, to $455 – $470 million,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- CORT Upcoming Earnings Report: What to Expect?
- Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
- Corcept announces publication of analysis of Phase 2 trial of relacorilant